Objective：To explore the effects and mechanisms of lobaplatin on antitumor immunity and programmed cell death 1（PD-1）expression in hepatocellular carcinoma（HCC）. Methods：①A total of 73 HCC patients were randomly divided into two groups：the lobaplatin group（50 mg lobaplatin in 100 ml sterile water was infused into abdominal cavity during liver cancer resection，n=40），and the control group（n=33）. The changes in peripheral blood lymphocyte subsets were analyzed before and after surgery. ②The effects of lobaplatin（16 μmol/L）on the expression of HLA-I，TAP-1，TAP-2 in Hep3B cells were analyzed by flow cytometry. ③Hep3B，HepG2，SMMC-7721 cells treated with lobaplatin（0，8，16 μmol/L）for 24 h，then the expressions of PD-L1，AKT，p-AKT protein were analyzed by Western blot and RT-qPCR. ④the expression of PD-L1 in Hep3B cells treated with lobaplatin，or lobaplatin and AKT-inhibitor MK2206 or PBS was analyzed by Western blot. Result：①After intraperitoneal infusion of lobaplatin，the rates of CD4+ and CD4+/CD8+ increased（P < 0.05），Treg decreased（P < 0.05）in the peripheral blood. ②Lobaplatin upregulated the expression of HLA-I，TAP1，and TAP2 in Hep3B cells. ③Lobaplatin upregulated the expression of PD-L1，p-AKT protein in HepG2，SMCC-7721，and Hep3B cells. ④AKT-inhibitor MK2206 reduced the effect of lobaplatin on the up-regulation of PD-L1 expression in Hep3B cells. Conclusion：Lobaplatin can enhance the anti-tumor immunity of HCC patients，induce antigen presentation of liver cancer cells and increase the expression of PD-L1 through AKT signal pathway，so that lobaplatin maybe combine with immune checkpoint inhibitor to treat HCC.